Skip to main content
. 2019 Aug 19;20(16):4038. doi: 10.3390/ijms20164038

Figure 2.

Figure 2

Tigecycline and minocycline suppress osteoclast formation from BMMs. (A) BMMs were treated with M-CSF and RANKL in the absence or the presence of increasing concentrations of tigecycline or minocycline for three days, and osteoclast formation was examined by tartrate-resistant acid phosphatase (TRAP) staining (left) and counting the number of TRAP-positive multinuclear osteoclasts (right). (B) BMMs were treated with M-CSF in the presence of tigecycline or minocycline, as in (A), and cell proliferation was measured by MTT assays. Error bars represent the mean result ± SD of three independent experiments; * p < 0.05, *** p < 0.0001 (ANOVA analysis).